Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | BRAF V600E |
| Therapy | Osimertinib |
| Indication/Tumor Type | lung adenocarcinoma |
| Response Type | predicted - resistant |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| BRAF V600E | lung adenocarcinoma | predicted - resistant | Osimertinib | Case Reports/Case Series | Actionable | In a clinical case study, acquisition of BRAF V600E and loss of EGFR G719A and EGFR S768I were identified in the post-progression biopsy of a patient with metastatic lung adenocarcinoma treated with Tagrisso (osimertinib) (PMID: 42398475). | 42398475 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (42398475) | Clonal divergence with acquired BRAF V600E in NSCLC with compound EGFR G719X/S768I after prolonged EGFR-TKI therapy. | Full reference... |